ArticleBlood2021

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.

Mehdi Hamadani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.